Cytogenetic studies at diagnosis in polycythemia vera: Clinical and JAK2V617F allele burden correlates

European Journal of Haematology

Volumn 80, Issue 3, 2008, Pages 197-200

  Gangat, Naseema ^a   Strand, Jacob ^a   Lasho, Terra L ^a   Finke, Christy M ^a   Knudson, Ryan A ^a   Pardanani, Animesh ^a   Li, Chin Yang ^a   Ketterling, Rhett P ^a   Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

Author keywords

Cytogenetics; Karyotype; Myeloid disorders; Polycythemia vera

Indexed keywords

ADULT; ALLELE; ARTICLE; BLEEDING; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYCYTHEMIA VERA; PRIORITY JOURNAL; THROMBOSIS; TRISOMY 8;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLELES; AMINO ACID SUBSTITUTION; BONE MARROW CELLS; CHROMOSOME ABERRATIONS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; PHENYLALANINE; POLYCYTHEMIA VERA; PROGNOSIS; RETROSPECTIVE STUDIES; VALINE;

EID: 39149086103     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2007.01003.x     Document Type: Article

References (13)

1. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005 434 : 1144 8.
2. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007 356: 459 68.
3. Larson RA, Kondo K, Vardiman JW, Butler AE, Golomb HM, Rowley JD. Evidence for a 15;17 translocation in every patient with acute promyelocytic leukemia. Am J Med 1984 76: 827 41.
4. de The H, Chomienne C, Lanotte M, Degos L, Dejean A. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature 1990 347: 558 61.
5. Druker BJ, Lydon NB. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 2000 105: 3 7.
6. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998 92: 2322 33.
7. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997 89: 2079 88.
8. Swolin B, Weinfeld A, Westin J. A prospective long-term cytogenetic study in polycythemia vera in relation to treatment and clinical course. Blood 1988 72: 386 95.
9. Diez-Martin JL, Graham DL, Petitt RM, Dewald GW. Chromosome studies in 104 patients with polycythemia vera. Mayo Clin Proc 1991 66: 287 99.
10. Dewald GW, Broderick DJ, Tom WW, Hagstrom JE, Pierre RV. The efficacy of direct, 24-hour culture, and mitotic synchronization methods for cytogenetic analysis of bone marrow in neoplastic hematologic disorders. Cancer Genet Cytogenet 1985 18: 1 10.
11. Levine RL, Belisle C, Wadleigh M, et al. X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis. Blood 2006 107: 4139 41.
12. Rege-Cambrin G, Mecucci C, Tricot G, et al. A chromosomal profile of polycythemia vera. Cancer Genet Cytogenet 1987 25: 233 45.
13. Testa JR, Kanofsky JR, Rowley JD, Baron JM, Vardiman JW. Karyotypic patterns and their clinical significance in polycythemia vera. Am J Hematol 1981 11: 29 45.